封面
市场调查报告书
商品编码
1587472

北美兽医肿瘤学市场规模、份额和趋势分析报告:2025-2030 年按动物、治疗、癌症、国家和细分市场进行的预测

North America Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal (Canine, Feline), By Therapy (Radiotherapy, Surgery, Chemotherapy), By Cancer (Skin Cancer, Lymphoma), By Country, And Segment Forecasts, 2025 - 2030

出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

北美兽医肿瘤学市场成长与趋势:

Grand View Research, Inc.最新报告显示,到2030年,北美兽用肿瘤市场规模预计将达到12.2亿美元,2025年至2030年复合年增长率为10.70%。

该市场的推动因素包括宠物癌症发病率的上升、调查各种癌症治疗的安全性和有效性的兽医临床试验的数量以及宠物保险普及率的上升。此外,针对伴同性动物癌症标靶治疗的研究和开发的策略性倡议不断增加正在推动市场成长。例如,2023 年 7 月,Ardent Animal Health 与 FidoCure 合作,利用后者的基因组测试和精准医疗平台,扩大兽医肿瘤学创新的应用范围。

在 COVID-19 期间,由于面临多项挑战,市场成长缓慢。这场流行病影响了兽医癌症研究和开发工作以及关键宠物药品的后勤供应。获得兽医护理的机会也受到限制。根据世界动物健康协会2020年报告,对宠物饲主的一项调查发现,在许多国家,兽医服务因宠物兽医护理的延误或遗漏而受到阻碍。但这场大流行也加速了数位科技的采用,以加强护理。 2020 年 3 月,PetCure Oncology 升级了其远距医疗选项,让宠物家庭和转诊兽医与公司经过董事会认证的放射肿瘤科医生进行远端连接。

由于存在多个从小到大的市场参与者,市场分散且竞争激烈。参与者正在积极部署策略性倡议来获得市场占有率。例如,2022年1月,Decra从Anivive Life Sciences收购了Labeldia-CA1(Vergynexol片剂)在美国的销售、行销和支援权。 2022年6月,勃林格殷格翰国际股份有限公司与生物製药公司CarthroniX建立研究伙伴关係,开发犬隻癌症领域的小分子疗法。 2023 年 4 月,Torigen Pharmaceuticals 将与兽医管理集团 (VMG) 合作,向 VMG 的 2,000 多家会员诊所网路提供该公司的实验性自製产品和服务。

北美兽医肿瘤学市场报告亮点

  • 从动物类型来看,2024 年犬类市场占据主导地位,占销售份额超过 86.25%。同时,猫科动物预计在预测期内将以超过 12.38% 的复合年增长率增长最快。这是由伙伴关係和研究合作的增加所推动的,以加速可靠的兽医癌症治疗的开发和商业化。例如,2022 年 10 月,Ardent Animal Health 完成了一项用于治疗狗癌症的新型查核点抑制剂的授权合约。
  • 从治疗方法来看,手术领域占据市场主导地位,2024年销售量超过36.09%。预计免疫治疗领域在预测期内将以最快的复合年增长率成长。
  • 按癌症类型划分,皮肤癌领域占据市场主导地位,2024年收益占有率将超过39.01%。预计其他细分市场在预测期内将以最快的复合年增长率成长。
  • 依国家划分,2024年美国兽用肿瘤市场占北美地区最大份额,达89.02%。美国的成长归功于关键参与者的存在和市场参与者的策略倡议。 2023 年 4 月,Torigen Pharmaceuticals 在美国康乃狄克州法明顿开设了新的生产设施和总部。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章北美兽医肿瘤学市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 北美兽医肿瘤学市场分析工具
    • 波特的分析
    • PESTEL分析
  • COVID-19 分析
  • 主要国家的宠物数量估计

第四章北美兽医肿瘤学市场:动物估计与趋势分析

  • 细分仪表板
  • 北美兽医肿瘤市场波动分析
  • 2018-2030年北美兽医肿瘤学市场规模与趋势分析(按动物)

第五章北美兽医肿瘤市场:治疗估计与趋势分析

  • 细分仪表板
  • 北美兽医肿瘤市场波动分析
  • 2018-2030 年北美兽医肿瘤市场规模与趋势分析(依治疗)
  • 放射治疗
    • 立体定位放射治疗
    • 常规放射线治疗
  • 外科手术
  • 化疗
  • 免疫疗法
  • 其他治疗

第六章北美兽医肿瘤市场:癌症类型估计与趋势分析

  • 细分仪表板
  • 北美兽医肿瘤市场波动分析
  • 2018-2030年北美兽医肿瘤学市场规模与趋势分析(依癌症类型)
  • 皮肤癌
  • 淋巴瘤
  • 肉瘤
  • 其他的

第七章北美兽医肿瘤市场:区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测及趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第八章 竞争格局

  • 市场参与企业分类
  • 企业市场分析/热图分析
  • 2023年企业市场占有率评估分析
  • 策略规划
    • 併购
    • 伙伴关係与协作
    • 其他的
  • 公司简介
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Zoetis
    • PetCure Oncology
    • Accuray Incorporated
    • Varian Medical Systems, Inc.
    • Elekta AB.
    • Karyopharm Therapeutics, Inc.
    • Virbac.
    • Merck &Co., Inc.
    • Dechra Pharmaceuticals PLC
    • NovaVive Inc.
    • Ardent Animal Health, LLC(A BreakthrU Company).

第 9 章 要点

Product Code: GVR-4-68040-138-7

North America Veterinary Oncology Market Growth & Trends:

The North America veterinary oncology market size is expected to reach USD 1.22 billion by 2030, expanding at a CAGR of 10.70% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising incidence of cancer in pets, the number of veterinary clinical trials investigating the safety and effectiveness of various oncologic therapies, and the increasing penetration of pet insurance. Moreover, increasing strategic initiatives for R&D of targeted therapies for cancer in companion animals is boosting market growth. For instance, in July 2023, Ardent Animal Health partnered with FidoCure to expand access to oncology innovation in veterinary medicine by leveraging the latter's genomic testing and precision medicine platform.

During COVID-19, the market witnessed dampened growth owing to several challenges. The pandemic impacted veterinary cancer research & development efforts and the logistics supply of crucial pet pharmaceuticals. It also limited access to veterinary care. According to the Global Animal Health Association's 2020 report, pet owners in a study said that in many countries, veterinarian services were hampered by delayed or skipped care for pets. The pandemic, however, also accelerated the adoption of digital technologies to enhance care. In March 2020, PetCure Oncology upgraded its Telehealth options to enable pet families and referring veterinarians to remotely connect with its board-certified radiation oncologists.

The market is fragmented and competitive due to the presence of several small-to-large market players. Players are actively involved in deploying strategic initiatives to gain market share. For instance, in January 2022, Dechra acquired the rights to sell, market, and support Laverdia-CA1 (verdinexor tablets) in the U.S. from Anivive Lifesciences, Inc. In June 2022, Boehringer Ingelheim International GmbH entered into a research partnership with CarthroniX, a biopharma company, to develop small molecule therapeutics in canine oncology. In April 2023, Torigen Pharmaceuticals partnered with Veterinary Management Groups (VMG) to provide their experimental autologous prescription products and services to the latter's more than 2,000 member clinics network.

North America Veterinary Oncology Market Report Highlights:

  • Based on animal type, the canine segment dominated the market in 2024 with a revenue share of over 86.25%. The feline segment, on the other hand, is projected to grow at the fastest CAGR of over 12.38% over the forecast period. This is attributed to the increasing partnerships and collaborations to further the development and launch of reliable veterinary cancer therapies. In October 2022, Ardent Animal Health, for example, completed a license agreement for a novel checkpoint inhibitor for canine cancer treatment
  • In terms of therapy, the surgery segment dominated the market in 2024 with a revenue share of over 36.09%. Immunotherapy segment is estimated to grow at the fastest CAGR over the forecast period.
  • Based on cancer type, the skin cancers segment dominated the market in 2024 with a revenue share of over 39.01%. The others segment is expected to grow at the fastest CAGR over the forecast period.
  • Based on country, The veterinary oncology market in the U.S. held the largest share of 89.02% in the North American region in 2024 The growth in the U.S. is attributed to the presence of key players and strategic initiatives by market players. In April 2023, Torigen Pharmaceuticals opened a new production facility and headquarters in Farmington, Connecticut, U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis
    • 1.6.2. Global Market: CAGR Calculation
  • 1.7. Research Scope and Assumptions
    • 1.7.1. List of Secondary Sources
    • 1.7.2. List of Primary Sources
    • 1.7.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Veterinary Oncology Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing Prevalence Of Cancer In Pets
      • 3.2.1.2. Increasing R&D In Pet Cancer Therapy
      • 3.2.1.3. Growing Focus On Animal Safety
      • 3.2.1.4. Growing Uptake Of Pet Insurance
      • 3.2.1.5. Technological Advancements In Pet Cancer Treatment
      • 3.2.1.6. Increase In Pet Population
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Adverse effects associated with therapies
      • 3.2.2.3. Complex Regulatory Guidelines
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. North America Veterinary Oncology Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal landscape
  • 3.4. Covid-19 Analysis
  • 3.5. Estimated Pet Population, by key countries

Chapter 4. North America Veterinary Oncology Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Veterinary Oncology Market Movement Analysis
  • 4.3. North America Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.4. Canine
    • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Feline
    • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Equine
    • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Veterinary Oncology Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Veterinary Oncology Market Movement Analysis
  • 5.3. North America Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Radiotherapy
    • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Stereotactic Radiation Therapy
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.2. LINAC
        • 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.3. Other Type
        • 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Conventional Radiation Therapy
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapy
    • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunotherapy
    • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Therapies
    • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Veterinary Oncology Market Movement Analysis
  • 6.3. North America Veterinary Oncology Market Size & Trend Analysis, by Cancer type, 2018 to 2030 (USD Million)
  • 6.4. Skin Cancer
    • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Lymphomas
    • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sarcomas
    • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. North America Veterinary Oncology Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Insights
      • 7.3.2.3. U.S. Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Insights
      • 7.3.3.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Insights
      • 7.3.4.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Estimated Company Market Share Analysis, 2023
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Others
  • 8.5. Company Profiles
    • 8.5.1. Elanco
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Boehringer Ingelheim International GmbH.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Zoetis
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. PetCure Oncology
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Accuray Incorporated
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Varian Medical Systems, Inc.
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Elekta AB.
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Karyopharm Therapeutics, Inc.
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Virbac.
      • 8.5.9.1. Participant's Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Merck & Co., Inc.
      • 8.5.10.1. Participant's Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Dechra Pharmaceuticals PLC
      • 8.5.11.1. Participant's Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. NovaVive Inc.
      • 8.5.12.1. Participant's Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
      • 8.5.13.1. Participant's Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives

Chapter 9. Key Takeaways

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 4 North America Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 North America Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 7 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 8 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 9 Canada Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 10 Canada Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 11 Canada Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 12 Mexico Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 13 Mexico Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 14 Mexico Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 15 Company Overview
  • Table 16 Service Benchmarking
  • Table 17 Financial Performance
  • Table 18 Strategic Initiatives

List of Figures

  • Fig. 1 North America Veterinary Oncology Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of North America Veterinary Oncology Market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2023 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2023
  • Fig. 17 North America Veterinary Oncology Market Dynamics
  • Fig. 18 Estimated animal population, 2018-2023 by key species and key countries
  • Fig. 19 North America Veterinary Oncology Market: PORTER's analysis
  • Fig. 20 North America Veterinary Oncology Market: PESTEL analysis
  • Fig. 21 North America Veterinary Oncology Market by Animal: Key Takeaways
  • Fig. 22 North America Veterinary Oncology Market by Animal, 2024 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Equine market, 2018 - 2030 (USD Million)
  • Fig. 26 Horses market, 2018 - 2030 (USD Million)
  • Fig. 27 North America Veterinary Oncology Market by Therapy: Key Takeaways
  • Fig. 28 North America Veterinary Oncology Market by Therapy, Market Share, 2024 & 2030
  • Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 LINAC market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
  • Fig. 38 North America Veterinary Oncology Market by Cancer Type: Key Takeaways
  • Fig. 39 North America Veterinary Oncology Market by Cancer Type, Market Share, 2024 & 2030
  • Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
  • Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 43 Other market, 2018 - 2030 (USD Million)
  • Fig. 44 Regional market share analysis, 2024 & 2030
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 U.S. Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Canada Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Mexico Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Market Participant Categorization
  • Fig. 54 Heat map analysis
  • Fig. 55 Strategic Framework